Travere Therapeutics, Inc.
TVTXReported to SECin USCIK 0001438533Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 96. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Option exercise | nothing paid20,000 shares | Sep 17, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | nothing paid | Option exercise | 20,000 | Sep 17, 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Open-market sell | $26,124400 shares | Sep 17, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | $26,124 | Open-market sell | 400 | Sep 17, 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Open-market sell | $121,0041,900 shares | Sep 17, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | $121,004 | Open-market sell | 1,900 | Sep 17, 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Open-market sell | $1,298,17520,735 shares | Sep 17, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | $1,298,175 | Open-market sell | 20,735 | Sep 17, 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Open-market sell | $1,703,24127,473 shares | Sep 17, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | $1,703,241 | Open-market sell | 27,473 | Sep 17, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and Travere Therapeutics, Inc. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
There are two charts here because there are two different amounts. A lobbying firm reports income: what it was paid. A company that lobbies for itself reports expenses: what it spent, under one of three accounting methods it picks itself. Both appear under this company, and they are not the same measurement — so they are never added, not in a bar and not in a total.
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.
Reported expenses: what this company reported spending on its own lobbying, per quarter, under the accounting method it picked itself.
Before 2025, these bars cover only the lobbying relationships that were still active in 2025 or later. Engagements that ended earlier are not included, so those years may be higher than shown.